These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis. Author: Gupta S, Sodhani P, Sharma A, Sharma JK, Halder K, Charchra KL, Sardana S, Singh V, Sehgal A, Das BC. Journal: Cytopathology; 2009 Aug; 20(4):249-55. PubMed ID: 19018810. Abstract: OBJECTIVE: To determine the prevalence of high-risk human papillomavirus (HR-HPV) 16/18 infection of uterine cervix among women in the reproductive age group, with cytologically normal cervical (Pap) smears; to analyse the risk factors for HR-HPV acquisition and to address their implications for cervical cancer screening and prophylaxis in a low resource setting. METHODS: Cervical samples from 769 cytologically negative women (age 18-45 years) attending a tertiary care centre in Delhi were subjected to HPV DNA testing and HR-HPV 16/18 and low-risk (LR)-HPV 6/11 sub-typing by polymerase chain reaction. Univariate risk factor analysis was carried out in HR-HPV positive (n = 86) versus HR-HPV negative women (n = 683) by chi-square test. RESULTS: The overall HPV prevalence among cytologically normal women was 16.6%. HR-HPV16 was detected in 10.1%, whereas HPV18 was detected in 1% of women. HR-HPV 16/18 comprised 67% of the total HPV positives. There was no decline in HR-HPV positivity with age, and women aged 40-44 years were at significantly increased risk for HR-HPV prevalence (P = 0.03). Statistically significant associations of HR-HPV infection were found with risk factors such as high parity (P = 0.04), cervicitis/hypertrophic cervix (P = 0.01), unhealthy cervix (P = 0.04), rural residence (P = 0.03), low socioeconomic status (P = 0.01) and illiteracy (P = 0.07). CONCLUSIONS: Although the sample size was small, based on the observation that HR-HPV 16 and 18 contributed significantly to the overall HPV prevalence in our setting, we speculate that testing/prophylaxis for these prevalent high-risk types could perhaps make cervical cancer screening and preventive programmes cost-effective. Larger community-based studies on HPV prevalence and persistence are required to validate these findings before definitive recommendations can be made to the policy makers.[Abstract] [Full Text] [Related] [New Search]